Any feedback?
Literature summary for 3.4.14.5 extracted from
- Vildagliptin: a novel DPP-4 inhibitor with pancreatic islet enhancement activity for treatment of patients with type 2 diabetes (2006), Drugs Today, 42, 519-531.
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | vildagliptin is a DPP-4 inhibitor with pancreatic islet enhancement activity for treatment of patients with type 2 diabetes | Homo sapiens |
Inhibitors
| Inhibitors | Comment | Organism | Structure |
|---|---|---|---|
| vildagliptin | pharmacokinetic studies in patients with type 2 diabetes | Homo sapiens |  |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | - |
- |
- |
Source Tissue
| Source Tissue | Comment | Organism | Textmining |
|---|
Synonyms
| Synonyms | Comment | Organism |
|---|---|---|
| DPP-4 | - |
Homo sapiens |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
